|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/09/20 BioCardia, Inc. 10-K 12/31/19 86:6.7M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.13M
2: EX-4.10 Instrument Defining the Rights of Security Holders HTML 44K
3: EX-21.1 Subsidiaries List HTML 22K
4: EX-23.1 Consent of Experts or Counsel HTML 25K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
52: R1 Document And Entity Information HTML 64K
73: R2 Consolidated Balance Sheets HTML 105K
66: R3 Consolidated Balance Sheets (Parentheticals) HTML 45K
20: R4 Consolidated Statements of Operations HTML 85K
50: R5 Consolidated Statements of Stockholders' Equity HTML 81K
72: R6 Consolidated Statements of Stockholders' Equity HTML 25K
(Parentheticals)
65: R7 Consolidated Statements of Cash Flows HTML 121K
22: R8 Note 1 - Summary of Business HTML 31K
47: R9 Note 2 - Significant Accounting Policies HTML 149K
57: R10 Note 3 - Fair Value Measurements HTML 50K
84: R11 Note 4 - Inventories HTML 37K
41: R12 Note 5 - Property and Equipment, Net HTML 43K
33: R13 Note 6 - Lease HTML 54K
56: R14 Note 7 - Collaborative Agreements HTML 29K
83: R15 Note 8 - Accrued Expenses and Other Current HTML 39K
Liabilities
40: R16 Note 9 - Stockholders' Equity HTML 52K
32: R17 Note 10 - Share-based Compensation HTML 115K
58: R18 Note 11 - Concentrations HTML 29K
82: R19 Note 12 - Net Loss Per Share HTML 52K
44: R20 Note 13 - Income Taxes HTML 83K
16: R21 Note 14 - Contingencies HTML 33K
62: R22 Note 15 - Grant Funding HTML 29K
71: R23 Note 16 - Related Party Transactions HTML 37K
43: R24 Note 17 - Employee Benefit Plans HTML 34K
15: R25 Note 18 - Subsequent Events HTML 31K
61: R26 Significant Accounting Policies (Policies) HTML 224K
70: R27 Note 2 - Significant Accounting Policies (Tables) HTML 30K
42: R28 Note 3 - Fair Value Measurements (Tables) HTML 46K
17: R29 Note 4 - Inventories (Tables) HTML 35K
30: R30 Note 5 - Property and Equipment, Net (Tables) HTML 40K
37: R31 Note 6 - Lease (Tables) HTML 55K
85: R32 Note 8 - Accrued Expenses and Other Current HTML 37K
Liabilities (Tables)
59: R33 Note 9 - Stockholders' Equity (Tables) HTML 36K
31: R34 Note 10 - Share-based Compensation (Tables) HTML 106K
38: R35 Note 12 - Net Loss Per Share (Tables) HTML 51K
86: R36 Note 13 - Income Taxes (Tables) HTML 72K
60: R37 Note 2 - Significant Accounting Policies 1 HTML 66K
(Details Textual)
29: R38 Note 2 - Significant Accounting Policies 2 HTML 32K
(Details Textual)
39: R39 Note 2 - Significant Accounting Policies - HTML 34K
Estimated Useful Lives of Property and Equipment
(Details)
23: R40 Note 3 - Fair Value Measurements - Fair Value of HTML 31K
Assets Measured on a Recurring Basis (Details)
48: R41 Note 4 - Inventories (Details Textual) HTML 27K
74: R42 Note 4 - Inventories - Summary of Inventories HTML 34K
(Details)
63: R43 Note 5 - Property and Equipment, Net (Details HTML 25K
Textual)
24: R44 Note 5 - Property and Equipment, Net - Summary of HTML 42K
Property and Equipment, Net (Details)
49: R45 Note 6 - Lease (Details Textual) HTML 25K
75: R46 Note 6 - Lease - Impact of New Lease Standard HTML 34K
(Details)
64: R47 Note 6 -Lease - Supplement Cash Flow Information HTML 26K
(Details)
21: R48 Note 6 - Lease - Future Minimum Lease Payments HTML 33K
Under Operating Lease (Details)
51: R49 Note 6 -Lease - Future Minimum Lease Payments HTML 34K
(Details)
36: R50 Note 8 - Accrued Expenses and Other Current HTML 37K
Liabilities - Summary of Accrued Expenses and
Other Current Liabilities (Details)
26: R51 Note 9 - Stockholders' Equity (Details Textual) HTML 116K
54: R52 Note 9 - Stockholders' Equity - Warrants (Details) HTML 30K
80: R53 Note 10 - Share-based Compensation (Details HTML 70K
Textual)
35: R54 Note 10 - Share-based Compensation - Share-based HTML 32K
Compensation Expense (Details)
25: R55 Note 10 - Share-based Compensation - Stock Option HTML 61K
Activity (Details)
53: R56 Note 10 - Share-based Compensation - Valuation HTML 39K
Assumptions for Employee Stock Options (Details)
79: R57 Note 10 - Share-based Compensation - Summary of HTML 46K
Non-vested RSUs (Details)
34: R58 Note 10 - Share-based Compensation - Nonemployee HTML 39K
Stock Option Valuation Assumptions (Details)
27: R59 Note 11 - Concentrations (Details Textual) HTML 37K
68: R60 Note 12 - Net Loss Per Share - Basic and Diluted HTML 39K
Net Income (Loss) Per Share (Details)
78: R61 Note 12 - Net Loss Per Share - Anti-dilutive HTML 32K
Securities (Details)
46: R62 Note 13 - Income Taxes (Details Textual) HTML 46K
19: R63 Note 13 - Income Taxes - Effective Income Tax HTML 45K
Reconciliation (Details)
67: R64 Note 13 - Income Taxes - Components of the Net HTML 44K
Deferred Income Tax Assets (Details)
77: R65 Note 13 - Income Taxes - Aggregate Changes in the HTML 28K
Balance of Gross Unrecognized Tax Benefits
(Details)
45: R66 Note 15 - Grant Funding (Details Textual) HTML 33K
18: R67 Note 16 - Related Party Transactions (Details HTML 70K
Textual)
69: R68 Note 17 - Employee Benefit Plans (Details Textual) HTML 27K
76: R69 Note 18 - Subsequent Events (Details Textual) HTML 33K
55: XML IDEA XML File -- Filing Summary XML 154K
81: EXCEL IDEA Workbook of Financial Reports XLSX 74K
9: EX-101.INS XBRL Instance -- bcda-20191231 XML 1.51M
11: EX-101.CAL XBRL Calculations -- bcda-20191231_cal XML 139K
12: EX-101.DEF XBRL Definitions -- bcda-20191231_def XML 1.19M
13: EX-101.LAB XBRL Labels -- bcda-20191231_lab XML 947K
14: EX-101.PRE XBRL Presentations -- bcda-20191231_pre XML 1.23M
10: EX-101.SCH XBRL Schema -- bcda-20191231 XSD 190K
28: ZIP XBRL Zipped Folder -- 0001437749-20-007405-xbrl Zip 161K
Exhibit 32.2
Certification of Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, David McClung, the Vice President of Finance of BioCardia, Inc. (the "Company"), hereby certify, that, to my knowledge:
1. The Annual Report on Form 10-K for the year ended December 31, 2019 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 9, 2020
|
|
/s/ David McClung |
|
|
|
Name: David McClung |
|
|
|
Title: Chief Financial Officer |
|
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/9/20 | 8-K | ||
| For Period end: | 12/31/19 | 4, NT 10-K | ||
| List all Filings | ||||